Disorders of phosphate homeostasis from CKD, vitamin D abnormalities, refeeding, or tumor lysis.
Also known as: hyperphosphatemia, hypophosphatemia, phosphate disorder, phosphorus disorder, refeeding syndrome
Overview
Hyperphosphatemia is serum phosphate >4.5 mg/dL in adults (>7 in young children). Hypophosphatemia is serum phosphate <2.5 mg/dL, with severe <1.0 mg/dL. Phosphate homeostasis is regulated by dietary intake, intestinal absorption (1,25-dihydroxyvitamin D dependent), renal excretion (PTH and FGF-23 dependent), and shifts between extracellular and intracellular compartments.
Epidemiology
Hyperphosphatemia is nearly universal in advanced CKD (eGFR <30) and end-stage renal disease. Hypophosphatemia occurs in ~5% of hospitalized patients and up to 30% of ICU patients, often from refeeding, sepsis, diabetic ketoacidosis recovery, or alcohol use disorder.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Hyperphosphatemia and Hypophosphatemia outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Hyperphosphatemia: CKD/ESKD (most common), tumor lysis syndrome, rhabdomyolysis, hypoparathyroidism, vitamin D toxicity, phosphate-containing bowel preps and laxatives, acidosis, hemolysis (artifactual)
Hypophosphatemia: refeeding syndrome (malnutrition, anorexia, alcoholism, post-bariatric), DKA recovery, respiratory alkalosis (intracellular shift), primary or secondary hyperparathyroidism, X-linked hypophosphatemic rickets, oncogenic osteomalacia (FGF-23–secreting tumor), Fanconi syndrome, IV iron (ferric carboxymaltose, iron isomaltoside), prolonged thiazide or loop diuretic use, vitamin D deficiency
Pathophysiology
Hyperphosphatemia: reduced renal excretion (low GFR) is the dominant mechanism in CKD; high turnover (tumor lysis, rhabdo) or transcellular shift (acidosis) contributes acutely. Chronic hyperphosphatemia drives FGF-23 release, secondary hyperparathyroidism, and CKD-MBD with vascular calcification. Hypophosphatemia: result of decreased intake, decreased absorption, transcellular shift (refeeding insulin surge, respiratory alkalosis), or increased renal loss (PTH, FGF-23 excess, Fanconi). Severe depletion impairs ATP, 2,3-DPG, and cellular function.
Clinical presentation
Symptoms
Hyperphosphatemia: often asymptomatic; pruritus, bone pain, soft-tissue calcification; symptoms of hypocalcemia (precipitation as calcium phosphate) — paresthesias, tetany, seizures
Hyperphosphatemia: signs of associated hypocalcemia (Chvostek, Trousseau), calciphylaxis lesions in ESKD, evidence of vascular calcification
Hypophosphatemia: proximal muscle weakness, decreased respiratory effort, rhabdomyolysis (dark urine, CK elevation), congestive heart failure in severe deficit
Classic findings
Calciphylaxis (ischemic skin necrosis) in dialysis patients with chronically elevated calcium-phosphate product. Refeeding syndrome with severe hypophosphatemia within 72 h of nutrition initiation in a starved patient.
Refeeding syndrome — Severe hypophosphatemia within 72 h of refeeding in a starved or alcoholic patient; also low K, Mg
X-linked hypophosphatemic rickets — FGF-23 excess, low phosphate, normal calcium, short stature, bowing of legs
Oncogenic osteomalacia — Adult with bone pain and severe hypophosphatemia; elevated FGF-23 from mesenchymal tumor
Diagnostic workup
Diagnostic criteria
Cutoffs vary slightly by lab. KDIGO CKD-MBD recommends keeping phosphate in the normal range in CKD patients on dialysis. Hypophosphatemia severity: mild 2.0-2.5, moderate 1.0-2.0, severe <1.0 mg/dL — treatment thresholds depend on severity and symptoms.
Labs
Serum phosphate (fasting; nonhemolyzed) — confirm with repeat sample
Calcium (total and ionized), albumin, magnesium, PTH, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D
BMP, eGFR, BUN/Cr
Urine phosphate (24-hour or fractional excretion of phosphate, FEPO4) to assess renal handling — high in renal wasting, low in intake/shift causes
If unclear etiology: FGF-23 level (elevated in X-linked hypophosphatemia, oncogenic osteomalacia, CKD-MBD), urine glucose/amino acids (Fanconi screen)
CBC, CK, LDH, uric acid (tumor lysis evaluation if relevant)
Imaging
DEXA scan if chronic phosphate disorder
Plain films/MRI for fractures, looser zones (osteomalacia)
68Ga-DOTATATE PET or octreotide scan for suspected FGF-23–secreting tumor
Hypophosphatemia (mild-moderate, asymptomatic): oral repletion — sodium or potassium phosphate (Phos-Nak, K-Phos Neutral); milk and dairy are practical sources
Hypophosphatemia (severe or symptomatic): IV phosphate — sodium phosphate or potassium phosphate; max 0.08-0.16 mmol/kg over 6 hours; monitor calcium (avoid precipitation)
Tumor lysis syndrome
Aggressive IV fluids (isotonic saline 2-3 L/m²/day)
Rasburicase for hyperuricemia
Phosphate binders, dialysis if severe
Avoid IV calcium unless symptomatic — risk of calcium phosphate precipitation
Refeeding syndrome
Start nutrition at 25-50% of goal and advance over 5-7 days
Replete phosphate, potassium, magnesium, and thiamine BEFORE and during refeeding
Severe hypophosphatemia (<1.0 mg/dL) can cause acute respiratory failure from diaphragmatic weakness — always check phosphate in unexplained ventilator dependence.
Watch for refeeding syndrome in anorexia, alcoholism, post-bariatric, and prolonged NPO patients — start nutrition slowly and pre-replete electrolytes.
Calcium-containing binders can worsen vascular calcification — non-calcium binders (sevelamer, lanthanum, ferric citrate) are preferred in dialysis patients with vascular disease.
IV ferric carboxymaltose is an underrecognized cause of hypophosphatemia, sometimes severe and prolonged.
Hyperphosphatemia + hypocalcemia + hyperuricemia + hyperkalemia + AKI = tumor lysis syndrome until proven otherwise.
References
KDIGO CKD-MBD 2017 — KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-Mineral and Bone Disorder (Kidney Int Suppl 2017;7:1-59)
Endocrine Society 2020 — Clinical Practice Guideline on X-linked Hypophosphatemia (Carpenter TO et al., JCEM 2020;105:1009-1023)
Refeeding — Friedli N et al. Refeeding syndrome: revisiting the etiology and management (Nutrition 2017;35:151-160)
Tumor lysis — Coiffier B et al. Guidelines for the management of tumor lysis syndrome in adults and children with malignancies (JCO 2008;26:2767-2778)
Practice Renal/Urology questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.